A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F. Brown, Paul Mulholland, Graham Searle et al.|Neuro-Oncology|2018Cited by 83
Dose-Finding Quantitative <sup>18</sup>F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic MalignanciesHatice Güngör, Hani Gabra, Edward Curry et al.|Journal of Nuclear Medicine|2015Cited by 27
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.Hatice Güngör, Hani Gabra, Deborah A. Smith et al.|Journal of Clinical Oncology|2011Cited by 14
ATNT-06EVALUATION OF THE SAFETY OF GSK2256098 AND PHARMACOKINETICS OF<sup>11</sup>C-GSK2256098 IN PATIENTS WITH RECURRENT GLIOBLASTOMA BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGINGPaul Mulholland, Sarah P. Blagden, Graham Searle et al.|Neuro-Oncology|2015Cited by 3